PDCD1 and non-small cell lung carcinoma: On the other hand, a recent study et al. in 44 NSCLC patients treated with trials of PD-1 and PD-L1 inhibitors, 4 patients (9%), all of whom received PD-L1 inhibitors, had experienced pseudoprogression at 3 months of therapy [28].